Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study

被引:116
作者
Tempesta, E
Janiri, L
Bignamini, A
Chabac, S
Potgieter, A
机构
[1] Univ Cattolica Sacro Cuore, Fac Med & Chirurg Agostino Gemelli, Inst Psychiat, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Inst Pharmacol, Rome, Italy
[3] HyperPhar, Milan, Italy
[4] Lipha Merck, Lyon, France
来源
ALCOHOL AND ALCOHOLISM | 2000年 / 35卷 / 02期
关键词
D O I
10.1093/alcalc/35.2.202
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The objective of this study was to compare acamprosate with placebo in the treatment of alcohol-dependent patients during a 6-month post-detoxification treatment and a 3-month medication-free follow-up. Patients (n = 330) were detoxified and randomized to treatment with acamprosate (1998 mg/day) or placebo within an out-patient programme including medical counselling, psychotherapy and self-help groups. The main outcome criterion was drinking behaviour as assessed by: abstinence/relapse ratio, cumulative abstinence duration (CAD) and the period of continued abstinence. Anxiety, depression and craving were also monitored. Intention to treat (ITT) statistical principles were followed. Twenty-five per cent of patients dropped out over the first 6 months. At the end of the treatment period, the abstinence rate was 57.9% for acamprosate and 45.2% for placebo (P = 0.03). The CAD was 110 +/- 77 days for acamprosate and 89 +/- 77 days for placebo (P = 0.016). Patients on acamprosate had a higher continuous abstinence rate and experienced less severe relapses. No differential effect was noted for anxiety, depression or craving. Treatment remained positive, but not significant, 3 months after termination of study medication. No significant difference in adverse events was noted between treatment groups. Acamprosate treatment over 180 days was consistently more effective than placebo to maintain abstinence and to diminish relapse severity.
引用
收藏
页码:202 / 209
页数:8
相关论文
共 24 条
  • [1] [Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
  • [2] Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225
  • [3] Emrick C.D., 1993, RES ALCOHOLICS ANONY, P41
  • [4] DETECTING ALCOHOLISM - THE CAGE QUESTIONNAIRE
    EWING, JA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (14): : 1905 - 1907
  • [5] EFFECTS OF FLUOXETINE AND CA-ACETYL-HOMOTAURINATE ON ALCOHOL INTAKE IN FAMILIAL AND NONFAMILIAL ALCOHOLIC PATIENTS
    GERRA, G
    CACCAVARI, R
    DELSIGNORE, R
    BOCCHI, R
    FERTONANI, G
    PASSERI, M
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1992, 52 (02): : 291 - 295
  • [6] GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311
  • [7] GUY W, 1996, ARCH GEN PSYCHIAT, V53, P76
  • [8] THE ASSESSMENT OF ANXIETY-STATES BY RATING
    HAMILTON, M
    [J]. BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1959, 32 (01): : 50 - 55
  • [9] Hamilton M., 1967, British Journal of Social and Clinical Psychology, V6, P278
  • [10] HILLEMAND B, 1985, REV ALCOOL, V30, P204